Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
![Foto de Cancer Center Clínica Universidad de Navarra (CCUN)](/img/uploaded/C185D7383C9859310EFAE5D78F321270.jpg)
![Foto de Hannover Medical School](/img/noimage_org.png)
Hannover Medical School
Hanóver, AlemaniaPublicaciones en colaboración con investigadores/as de Hannover Medical School (38)
2024
-
Robotic Versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients
Annals of Surgery, Vol. 280, Núm. 1, pp. 108-117
2023
-
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients
Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309
2022
-
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726
-
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255](S0923753419317119)(10.1093/annonc/mdy308)
Annals of Oncology
-
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
ESMO Open, Vol. 7, Núm. 2
-
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT
British Journal of Haematology
-
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
The Lancet, Vol. 399, Núm. 10319, pp. 61-116
2021
-
Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction
Nucleic Acids Research, Vol. 49, Núm. 9, pp. 5057-5073
-
AdrA as a Potential Immunomodulatory Candidate for STING-Mediated Antiviral Therapy That Required Both Type I IFN and TNF-α Production
Journal of immunology (Baltimore, Md. : 1950), Vol. 206, Núm. 2, pp. 376-385
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
Leukemia, Vol. 35, Núm. 12, pp. 3542-3550
-
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
Annals of Oncology